Advanced search
Publication Cover
Infection Ecology & Epidemiology Volume 10, 2020 - Issue 1
Submit an article Journal homepage
2,576
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test

Yang De Marinisa Department of Clinical Sciences, Lund University, Malmö, Sweden;b Clinical Research Hospital, Chinese Academy of Sciences; Department of Endocrinology and Metabolism, Division of Life Sciences of Medicine, University of Science and Technology of China, Hefei, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8081-2142View further author information
ORCID Icon,
Torgny Sunnerhagenc Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, SwedenORCID Iconhttps://orcid.org/0000-0002-9240-2378View further author information
ORCID Icon,
Pradeep Bompadaa Department of Clinical Sciences, Lund University, Malmö, SwedenView further author information
,
Anna Bläckbergc Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, SwedenView further author information
,
Runtao Yangd School of Mechanical, Electrical and Information Engineering, Shandong University, Weihai, ChinaView further author information
,
Joel Svenssone Clinical Chemistry, Lund University, Lund, SwedenView further author information
,
Ola Ekströma Department of Clinical Sciences, Lund University, Malmö, SwedenView further author information
,
Karl-Fredrik Erikssonf Department of Endocrinology, Wallenberg Laboratory, University Hospital MAS, Lund University, Malmö, SwedenView further author information
,
Ola Hanssona Department of Clinical Sciences, Lund University, Malmö, Sweden;g Finnish Institute of Molecular Medicine, University of Helsinki, Helsinki, FinlandView further author information
,
Leif Groopa Department of Clinical Sciences, Lund University, Malmö, Sweden;g Finnish Institute of Molecular Medicine, University of Helsinki, Helsinki, FinlandView further author information
,
Isabel Gonçalvesh Cardiovascular Research-Translational Studies, Department of Clinical Sciences Malmö and Department of Cardiology, Skåne University Hospital, Lund University, Lund, SwedenView further author information
&
Magnus Rasmussenc Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, SwedenORCID Iconhttps://orcid.org/0000-0003-1588-5473View further author information
ORCID Icon show all
Article: 1821513 | Received 03 Jun 2020, Accepted 26 Aug 2020, Published online: 20 Sep 2020

Figures & data

Table 1. Serology assessment of COVID-19 IgG and IgM response by COVID-19 Antibody Test IgM/IgG (ZetaGene, Sweden) in sera collected from hospitalized (n = 12) and non-hospitalized (n = 33) PCR-confirmed COVID-19 patients.

Figure 1. Serum SARS-Cov-2 IgM and IgG antibody detection in response to hospitalization in COVID-19 patients. IgM and IgG reactivity to SARS-CoV-2 was measured in sera in patients with PCR-confirmed COVID-19 (n = 45) by lateral flow test COVID-19 Antibody test IgM/IgG (ZetaGene, Sweden). Total IgM, IgG and total antibody detection percentage (%) are presented for the hospitalized (red bars, n = 12) and non-hospitalized patients (black bars, n = 33).

Figure 1. Serum SARS-Cov-2 IgM and IgG antibody detection in response to hospitalization in COVID-19 patients. IgM and IgG reactivity to SARS-CoV-2 was measured in sera in patients with PCR-confirmed COVID-19 (n = 45) by lateral flow test COVID-19 Antibody test IgM/IgG (ZetaGene, Sweden). Total IgM, IgG and total antibody detection percentage (%) are presented for the hospitalized (red bars, n = 12) and non-hospitalized patients (black bars, n = 33).

Figure 2. The distribution of COVID-19 IgM and IgG detection in hospitalized vs. non-hospitalized patients. Qualitative detection of IgM and IgG to SARS-CoV-2 was assessed in sera of hospitalized (n = 12) and non-hospitalized (n = 33) COVID-19 patients. IgG and IgM positivity and distribution (%) in the COVID-19 patients are presented in respective color as indicated in the figure.

Figure 2. The distribution of COVID-19 IgM and IgG detection in hospitalized vs. non-hospitalized patients. Qualitative detection of IgM and IgG to SARS-CoV-2 was assessed in sera of hospitalized (n = 12) and non-hospitalized (n = 33) COVID-19 patients. IgG and IgM positivity and distribution (%) in the COVID-19 patients are presented in respective color as indicated in the figure.

Table 2. Serology assessment of COVID-19 IgG and IgM response by COVID-19 Antibody Test IgM/IgG (ZetaGene, Sweden) in PCR-confirmed COVID-19 patients with time after onset <2 weeks (n = 8).

Table 3. Serology assessment of COVID-19 IgG and IgM response by COVID-19 Antibody Test IgM/IgG (ZetaGene, Sweden) in PCR-confirmed non-hospitalized COVID-19 patients with time after onset >2 weeks (n = 26).

Table 4. Serology assessment of COVID-19 IgG and IgM response by COVID-19 Antibody Test IgM/IgG (ZetaGene, Sweden) in PCR-confirmed hospitalized COVID-19 patients with time after onset >2 weeks (n = 11).

Figure 3. The distribution of antibody detection in response to time from onset and hospitalization. Total IgM, IgG and total antibody detection percentage (%) are presented for PCR-confirmed COVID-19 patients divided into the following groups: (1) acute patients with < 2 weeks (w) after onset (n = 8); (2) convalescent patients with > 2 weeks after onset, non-hospitalized (n = 26); (3) convalescent patients with > 2 weeks after onset, hospitalized (n = 11). Different groups are presented in respective colors as indicated in the figure.

Figure 3. The distribution of antibody detection in response to time from onset and hospitalization. Total IgM, IgG and total antibody detection percentage (%) are presented for PCR-confirmed COVID-19 patients divided into the following groups: (1) acute patients with < 2 weeks (w) after onset (n = 8); (2) convalescent patients with > 2 weeks after onset, non-hospitalized (n = 26); (3) convalescent patients with > 2 weeks after onset, hospitalized (n = 11). Different groups are presented in respective colors as indicated in the figure.

Figure 4. The dynamics of COVID-19 IgM/IgG detection in response to time from onset and hospitalization. Qualitative detection of IgM and IgG to SARS-CoV-2 is mapped in COVID-19 cohort patients from the following groups: (1) acute patients with < 2 weeks (w) after onset (n = 8); (2) convalescent patients with > 2 weeks after onset, non-hospitalized (n = 26); (3) convalescent patients with > 2 weeks after onset, hospitalized (n = 11). IgM and IgG detection percentage (%) is presented in respective color as indicated in the figure.

Figure 4. The dynamics of COVID-19 IgM/IgG detection in response to time from onset and hospitalization. Qualitative detection of IgM and IgG to SARS-CoV-2 is mapped in COVID-19 cohort patients from the following groups: (1) acute patients with < 2 weeks (w) after onset (n = 8); (2) convalescent patients with > 2 weeks after onset, non-hospitalized (n = 26); (3) convalescent patients with > 2 weeks after onset, hospitalized (n = 11). IgM and IgG detection percentage (%) is presented in respective color as indicated in the figure.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.